YI-JOU TAI2021-02-042021-02-0420201470-0328https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083175506&doi=10.1111%2f1471-0528.16229&partnerID=40&md5=b4e6239d5426ff23f7e07ccd9699f120https://scholars.lib.ntu.edu.tw/handle/123456789/547919[SDGs]SDG3chorionic gonadotropin; dactinomycin; methotrexate; chorionic gonadotropin; dactinomycin; methotrexate; cancer chemotherapy; cancer risk; drug efficacy; human; Note; priority journal; relapse; treatment duration; treatment failure; trophoblastic tumor; female; pregnancy; retrospective study; risk factor; trophoblastic tumor; Chorionic Gonadotropin; Dactinomycin; Female; Gestational Trophoblastic Disease; Humans; Methotrexate; Pregnancy; Retrospective Studies; Risk Factorsnote10.1111/1471-0528.16229322230112-s2.0-85083175506